Regeneron gets wrapped up in federal patient assistance investigation

Regeneron has been subpoenaed for information about its ties with patient assistance nonprofits.

The government’s probe of biopharma ties with patient assistance programs is growing into a who’s who of Big Biotech companies. After reaching out to Gilead Sciences, Celgene and Biogen, U.S. attorneys are asking Regeneron about its relationships with the nonprofits.

Regeneron disclosed in a SEC filing that it received a subpoena from the U.S. Attorney's Office for the District of Massachusetts for information and documents about its ties with patient assistance programs for drugs including Eylea, Praluent, Arcalyst and Zaltrap.

The nonprofits help patients afford expensive medicines, but they’ve come under fire as critics contend that pharma companies are using them to boost sales. Government regulations prohibit drugmakers from tying charitable donations to specific support for their own drugs.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Regeneron is cooperating with the feds, according to its filing. The company received the subpoena last month.

The news comes only a week after Biogen disclosed a federal subpoena for documents about government price reporting, rebate payments and its copay assistance programs for Avonex, Tecfidera, Tysabri and Plegridy.

Before Biogen, the feds asked for info from Celgene, Gilead, Horizon Pharma, Jazz and Valeant.

Aside from the governmental investigation, Celgene also faces a whistleblower suit claiming the company worked to “game the system” with contributions to steer charities toward its drugs. The company denied the charge.

For Regeneron, the disclosure came the same week it had a significant court win in an entirely different realm. It and marketing partner Sanofi won a crucial reprieve from a court on the PCSK9 drug Praluent, allowing the pair to continue selling the med during a patent fight with Amgen.

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.